Nanotherapeutic platforms for osteoarticular tuberculosis

Riyaz Ali M. Osmani, Ekta Singh, Rohit Bhosale, Rudra Vaghela, Vandana Patravale

Research output: Chapter in Book/Report/Conference proceedingChapter


Osteoarticular tuberculosis is a fairly ordinary extrapulmonary tuberculosis with about 10%-20% of all diagnosed tuberculosis cases falling under this category. Conventional interventions have included chemotherapy as the primary line of treatment. However, over the years the development of multiple drug resistance in tuberculosis has posed a far greater challenge, rendering the conventional therapy ineffective. Moreover, the disease progression leads to kyphosis, which requires advanced surgical interventions that are not patient-compliant considering that the bones are located deep beneath tissues. Thus, in order to achieve more target specificity in drug delivery, bone-targeted nanotherapeutics with dose reduction and shorter treatment duration are being explored as an alternative strategy. In this chapter, we focus on the various nanoformulation-based therapeutics as well as combinatorial therapies based on surgical interventions with nanoformulations and scaffold technology. These are currently being tested for the successful clinical treatment of osteoarticular tuberculosis. Furthermore, we review the limitations and future perspectives of nanotherapeutics in the effective, patient-compliant management of osteoarticular tuberculosis and bone regeneration.

Original languageEnglish (US)
Title of host publicationA Mechanistic Approach to Medicines for Tuberculosis Nanotherapy
Number of pages25
ISBN (Electronic)9780128199855
StatePublished - Jan 1 2021
Externally publishedYes


  • Bone regeneration
  • Chemotherapy
  • Extrapulmonary tuberculosis
  • Nanotechnology
  • Nanotherapeutics
  • Osteoarticular tuberculosis
  • Surgical interventions
  • Tuberculosis

ASJC Scopus subject areas

  • General Economics, Econometrics and Finance
  • General Business, Management and Accounting


Dive into the research topics of 'Nanotherapeutic platforms for osteoarticular tuberculosis'. Together they form a unique fingerprint.

Cite this